SavedAdd your journal

Journals / Glokom Katarakt / 2016 / Cilt: 11 - Sayı: 2

Topical Travaprost Associated with Facial Asymmetry

Topikal Travaprost Kullanımına Bağlı Fasiyal Asimetri

İLKE BAHÇECİ ŞİMŞEK
Özgür ARTUNAY
Pages
139–141
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Ophthalmologists should be aware of this potential side effect of topical travaprost, especially with monocular use as it ends up with facial asymmetry

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Seventy years old male patient was admitted to our clinic with facial asymmetry.
📊
Key Findings & Data:According to the detailed medical history of the patient travaprost eyedrops was being used for 1.5 years.
💡
Conclusion & Impact:Ophthalmologists should be aware of this potential side effect of topical travaprost, especially with monocular use as it ends up with facial asymmetry
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Seventy years old male patient was admitted to our clinic with facial asymmetry. In the ophthalmic examination, there was right upper eyelid ptosis, enophthalmus, upper displacement of the right eyebrow and the right scin crease. According to the detailed medical history of the patient travaprost eyedrops was being used for 1.5 years. In this case report we emphasize that travaprost, which is a topical prostaglandin analog, has an antiadipogenic effect leading to prostaglandin related periorbitopathy. We also emphasize that unnecessary cosmetic surgeries must be avoided since this effect is reversible when the eyedrop usage is discontinued. Ophthalmologists should be aware of this potential side effect of topical travaprost, especially with monocular use as it ends up with facial asymmetry

Özet

Yetmiş yaşında erkek hasta yüzde asimetri nedenli kliniğimize başvurdu. Yapılan göz muayenesinde sağ üst kapakta ptosis, enoftalmus, kaşta belirgin yukarı doğru pozisyon değişikliği, üst kapak kıvrımında silinme mevcuttu. Hastanın ayrıntılı sorgulamasında sağ göze 1,5 yıldır travaprost damla kullanımı dışında özellik yoktu. Bu vaka sunumu ile bir topikal prostaglandin analoğu olan travaprostun antiadipojenik etkiye bağlı periorbitopati gelişimine sebep olabileceğini ortaya koyduk. Bu durum ilaç kesildiğinde kendiliğinden düzelebilir, bu nedenle hastalara gereksiz kozmetik cerrahi yapılmamalıdır. Oftalmologlar prostaglandin analoglarının bu yan etkisini bilmeli ve özellikle monooküler kullanımda yüzde asimetri oluşturabilmesi nedeniyle daha dikkatli olmalıdır

🔖

Cite This Article

ŞİMŞEK, İ. B., ARTUNAY, Ö. (2016). Topical Travaprost Associated with Facial Asymmetry. Glokom Katarakt, Cilt: 11 - Sayı: 2, 139–141. https://ajindex.com/articles/226817

References (12)

  1. Quaranta L, Riva I, Katsanos A et al. Safety and efficacy of travoprost so- lution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015;9:633-43.
  2. Hughes BA, Bacharach J, Craven ER et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/ timolol 0.5% ophthalmic solution compared to travoprost 0.004% oph- thalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14:392-9.
  3. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bima- toprost therapy. Optom Vis Sci. 2004;81:574-7. Nakakura S,Yamamoto M, Terao E et al. Prostaglandin-associated perior- bitopathy in latanoprost users. Clin Ophthalmol. 2015;9:51-6.
  4. Kucukevcilioglu M, Bayer A, Uysal Y, et al. Prostaglandin associated peri- orbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Experiment Ophthalmol. 2014;42:126-31.
  5. Kucukevcilioglu M, Bayer A. Prostaglandin ilişkili periorbitopati: olgu sunumu ve temel fizyopatolojik hatırlatma. Turkish Journal Ophthalmol. 2013;1:57-60.
  6. Rabinowitz MP, Katz LJ, Moster MR et al. Unilateral prostaglandin-asso- ciated periorbitopathy: a syndrome involving upper eyelid retraction dis- tinguishable from the aging sunken eyelid. Ophthal Plast Reconstr Surg. 2015;31:373-8.
  7. Sakata R, Shirato S, Miyata K et al. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanop- rost ophthalmic solution. Eye (Lond). 2014;28:1446-51.
  8. Eftekhari K, Mifflin MD, Anderson RL. Prostaglandin-associated peri- orbital lipodystrophy in cosmetic eyelid surgery: a novel cause of facial asymmetry. Aesthet Surg J. 2015:184. Filippopoulos T, Paula JS, Torun N, et al. Periorbital changes associated with topical bimatoprost. Ophthal Plast Reconstr Surg. 2008;24:302-7.
  9. Stjernschantz JW, Albert DM, Hu DN et al. Mechanism and clinical sig- nificance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47:162-75.
  10. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47:185-202.
  11. Jayaprakasam, A., and Ghazi-Nouri, S. Periorbital fat atrophy-an unfami- liar side effect of prostaglandin analogues. Orbit 2010;29:357-9.
  12. Choi HY, Lee JE, LeeJW et al. In vitro study of antiadipogenic profile of latanoprost,travoprost, bimatoprost, and tafluprost in human orbital prea- diopocytes. J Ocul Pharmacol Ther. 2012;28:146-52. Kim JW. Topical prostaglandin analo